Testing how post-transplant cyclophosphamide affects transplant outcomes
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at whether giving a medicine called cyclophosphamide after a stem cell transplant helps work better and for whom. You may be eligible if you are planning a certain type of transplant and your team plans to give post-transplant cyclophosphamide.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (18 or older) at the time you sign consent
- Have your transplant team plan for you to receive a stem cell transplant at the study site (haplo-identical, matched related, or matched unrelated donor)
- Be able to understand and follow study steps for the whole study period
- If you are the recipient (person getting the transplant): your plan must include post-transplant cyclophosphamide
- If you’re a haplo-identical or matched related donor case: you must have a partner donor (or recipient) willing to sign the study consent as required
- No use of any other investigational (study) drug in the 30 days before the start of treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests giving cyclophosphamide after a specific type of stem cell transplant (haploidentical) in people age 65 and older. It aims to improve transplant safety and outcomes by adjusting medicine given after the graft is placed.
This trial studies giving cyclophosphamide after a stem cell transplant when there is no matched sibling donor, but a well-matched unrelated donor is available. It aims to improve outcomes for people with blood cancers undergoing this transplant.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
This trial tests whether a lower dose of the chemotherapy drug cyclophosphamide given after a stem cell transplant is safe and effective for people with blood cancers. The goal is to reduce side effects while still helping prevent the cancer from coming back.
This Phase 3 study tests whether giving post-transplant cyclophosphamide can better prevent a dangerous immune complication called GVHD compared with the usual standard medicines. You may be eligible if you are in remission from acute leukemia and planning a fully matched related-donor stem cell transplant.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Hear when a new Leukemia, Not Otherwise Specified trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.